Literature DB >> 195181

Prevalence of serum lipid abnormalities in chronic hemodialysis.

J D Brunzell, J J Albers, L B Haas, A P Goldberg, L Agadoa, D J Sherrard.   

Abstract

Fasting levels of serum triglyceride, cholesterol, high-density lipoprotein (HDL), apoprotein A-I, HDL cholesterol, and HDL triglyceride were measured in 94 uremic males receiving maintenance hemodialysis and 6 uremic males receiving chronic peritoneal dialysis. These patients had higher serum triglyceride levels (p less than 0.001) and lower cholesterol levels (p less than 0.001) than normal controls. The dialysis patients treated with androgen or propranolol and those who were hypothyroid or diabetic had significantly higher triglyceride levels than the other dialysis subjects. The dialysis patients who had no additional secondary causes of hypertriglyceridemia had abnormalities in HDL; in comparison to normals and triglyceride-matched controls, these patients had elevated HDL triglyceride levels and low HDL cholesterol levels, despite similar HDL apoprotein A-I levels. The HDL cholesterol levels appeared to be lower in those patients than could be accounted for by their degree of hypertriglyceridemia.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 195181     DOI: 10.1016/0026-0495(77)90009-9

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  14 in total

1.  Quantitation of high density lipoproteins.

Authors:  J J Albers; G R Warnick; M C Chenng
Journal:  Lipids       Date:  1978-12       Impact factor: 1.880

2.  High-density lipoprotein in chronic renal failure and after renal transplantation.

Authors:  E Savdie; J C Gibson; J H Stewart; L A Simons
Journal:  Br Med J       Date:  1979-04-07

3.  Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis.

Authors:  H Dieplinger; P Y Schoenfeld; C J Fielding
Journal:  J Clin Invest       Date:  1986-04       Impact factor: 14.808

Review 4.  The effects of diuretics and adrenergic-blocking agents on plasma lipids.

Authors:  J J Rohlfing; J D Brunzell
Journal:  West J Med       Date:  1986-08

Review 5.  Central and peripheral adaptations to physical training in patients with end-stage renal disease.

Authors:  E J Kouidi
Journal:  Sports Med       Date:  2001       Impact factor: 11.136

6.  Absorption and excretion of colestilan in healthy subjects.

Authors:  Koji Takei; Sian Dale; Heather Charles; Akira Sasaki; Shigekazu Nakajima
Journal:  Clin Pharmacokinet       Date:  2010       Impact factor: 6.447

Review 7.  [Alterations of fat metabolism in renal disease - pathogenetic mechanisms (author's transl)].

Authors:  W H Hörl; M Hörl; A Heidland
Journal:  Klin Wochenschr       Date:  1982-04-01

Review 8.  [Pathophysiology and therapy of lipid metabolism disorders in kidney diseases].

Authors:  C J Olbricht
Journal:  Klin Wochenschr       Date:  1991-08-01

9.  Apolipoprotein E phenotypes and hyperlipidemia in patients under maintenance hemodialysis.

Authors:  G Feussner; S Wey; J Bommer; D Deppermann; P Grützmacher; R Ziegler
Journal:  Hum Genet       Date:  1992-01       Impact factor: 4.132

10.  Biochemical markers of vascular calcification in elderly hemodialysis patients.

Authors:  Alvaro Osorio; Esperanza Ortega; Jesús M Torres; Pilar Sanchez; Estrella Ruiz-Requena
Journal:  Mol Cell Biochem       Date:  2012-11-03       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.